SANA
Sana Biotechnology, Inc.
$2.68
-3.25%
$745.8M
No data for this timeframe.
Vol
Market Cap$745.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$328.0M
Inst. Activity11 buys / 4 sells
Reddit Sentiment33° Cool
SEC Reports5
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001770121·Prev Close $2.77
Recent Activity
Jun 12, 2026
short_volume
Short Volume: SANA — 56.0% short (0.5M / 0.8M)
Short: 455,997 | Exempt: 1,067 | TRF Vol: 814,033 | Short Ratio: 56.0% | Off-exchange volume (dark p
Jun 4, 2026
Insider
Yang Patrick Y was granted 90,000 shares
Director
Jun 4, 2026
Insider
Rosiello Robert L. was granted 90,000 shares
Director
Jun 4, 2026
Insider
Seitz Michelle was granted 90,000 shares
Director
May 11, 2026
SEC
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but
PRESS-RELEASE — Impact 6/10
May 11, 2026
SEC
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than the $0.21 loss in Q1
8-K — Impact 4/10
Apr 24, 2026
SEC
Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and ratify the appointment
DEFA14A — Impact 4/10
Inst.
STATE STREET CORP — ADD
10,538,086 shares ($30.3M)
Price Targets
$8.57
+219.8% upside
Strong Buy
Current $2.68
Low $7.00
Median $7.00
High $12.00
7 analysts
$7.00
$12.00
Analyst Ratings
6Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 6, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▲ +18.2% | $-0.13 — $-0.10 | 25% YoY | 3 |
| Next Q | $-0.12 ▲ +17.8% | $-0.14 — $-0.10 | 18% YoY | 3 |
| Current FY | $-0.60 ▼ -2.6% | $-0.68 — $-0.53 | 11% YoY | 4 |
| Next FY | $-0.54 ▼ -1.4% | $-0.62 — $-0.42 | 10% YoY | 4 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but
May 11, 2026
NEUTRAL
8-K
4/10
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than the $0.21 loss in Q1
May 11, 2026
BULLISH
Press
7/10
Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development and clinical deliv
Apr 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $107.8M | — |
| BlackRock, Inc. | $41.0M | ADD |
| STATE STREET CORP | $30.3M | ADD |
| CANADA PENSION PLAN INVESTMENT | $29.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Yang Patrick | A | $0.00 |
| Jun 4, 2026 | Rosiello Robert | A | $0.00 |
| Jun 4, 2026 | Seitz Michelle | A | $0.00 |
| Jun 4, 2026 | Mulligan Richard | A | $0.00 |
| Jun 4, 2026 | REICIN ALISE | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $328.0M total value (113,802,686 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, STATE. Net buying activity: 11 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 37,430,284 | $107.8M | 32.9% | — |
| 2 | BlackRock, Inc. | 14,240,175 | $41.0M | 12.5% | ADD +26.7% |
| 3 | STATE STREET CORP | 10,538,086 | $30.3M | 9.3% | ADD +30.8% |
| 4 | CANADA PENSION PLAN INVESTMENT BOARD | 10,221,900 | $29.4M | 9.0% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 7,434,724 | $21.4M | 6.5% | — |
| 6 | BAILLIE GIFFORD & CO | 6,609,065 | $19.0M | 5.8% | TRIM -42.2% |
| 7 | Marex Group plc | 3,999,100 | $11.5M | 3.5% | — |
| 8 | GOLDMAN SACHS GROUP INC | 3,181,115 | $9.2M | 2.8% | — |
| 9 | BANK OF AMERICA CORP /DE/ | 2,946,861 | $8.5M | 2.6% | DOUBLED +148.4% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,707,521 | $4.9M | 1.5% | — |
| 11 | MORGAN STANLEY | 1,460,015 | $4.2M | 1.3% | ADD +46.6% |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 1,451,200 | $4.2M | 1.3% | DOUBLED +878.1% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,366,148 | $3.9M | 1.2% | — |
| 14 | Woodline Partners LP | 1,317,932 | $3.8M | 1.2% | ADD +76.4% |
| 15 | TWO SIGMA INVESTMENTS, LP | 1,198,579 | $3.5M | 1.1% | DOUBLED +158.9% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 1,063,649 | $3.1M | 0.9% | — |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1,033,804 | $3.0M | 0.9% | TRIM -38.4% |
| 18 | MARSHALL WACE, LLP | 664,457 | $1.9M | 0.6% | DOUBLED +648.4% |
| 19 | DEUTSCHE BANK AG\ | 591,911 | $1.7M | 0.5% | — |
| 20 | Invesco Ltd. | 569,186 | $1.6M | 0.5% | ADD +65.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 8,054,841 | 10,538,086 | +30.8% | $30.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,186,251 | 2,946,861 | +148.4% | $8.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 1,679,130 | 1,033,804 | -38.4% | $3.0M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 88,788 | 664,457 | +648.4% | $1.9M | 2026-Q1 |
| Rafferty Asset Management, LLC | ADD | 274,162 | 353,582 | +29.0% | $1.0M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 133,078 | 291,268 | +118.9% | $838.9K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 37,444 | 111,917 | +198.9% | $322.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 1,494 | 74,827 | +4908.5% | $215.5K | 2026-Q1 |
| MetLife Investment Management, LLC | TRIM | 93,126 | 66,551 | -28.5% | $191.7K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 70,607 | 52,810 | -25.2% | $152.1K | 2026-Q1 |
| Pictet Asset Management Holding SA | ADD | 18,081 | 32,132 | +77.7% | $92.5K | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 10,746 | 14,327 | +33.3% | $41.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 9,588 | 13,765 | +43.6% | $39.6K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 2,281 | 2,962 | +29.9% | $8.5K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | 766,487 | 207,492 | -72.9% | $598.00 | 2026-Q1 |
| BlackRock, Inc. | ADD | 11,226,136 | 14,223,527 | +26.7% | $57.9M | 2025-Q4 |
| BAILLIE GIFFORD & CO | TRIM | 11,436,503 | 6,609,065 | -42.2% | $26.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 610,128 | 1,579,705 | +158.9% | $6.4M | 2025-Q4 |
| MORGAN STANLEY | ADD | 876,505 | 1,285,045 | +46.6% | $5.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 917,642 | 1,186,251 | +29.3% | $4.8M | 2025-Q4 |
| BAKER BROS. ADVISORS LP | NEAR_EXIT | 2,030,949 | 310,483 | -84.7% | $1.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 106,366 | 191,081 | +79.6% | $777.7K | 2025-Q4 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 25,003 | 163,536 | +554.1% | $665.6K | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | NEAR_EXIT | 778,126 | 133,078 | -82.9% | $541.6K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 198,179 | 128,856 | -35.0% | $524.4K | 2025-Q4 |
10 unique insiders with 21 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Yang Patrick Y | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Rosiello Robert L. | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Seitz Michelle | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Mulligan Richard | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | REICIN ALISE | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Bilenker Joshua H. | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Bishop Hans Edgar | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | NELSEN ROBERT | Director | AWARD | 90,000 | — | — |
| Apr 6, 2026 | Bishop Hans Edgar | Director | AWARD | 7,763 | — | — |
| Mar 9, 2026 | Wyrick Susan D. | See Remarks | TAX W/H | 3,342 | $3.13 | $10.5K |
| Mar 9, 2026 | Harr Steve | President & CEO | TAX W/H | 11,526 | $3.13 | $36.1K |
| Mar 7, 2026 | Harr Steve | President & CEO | EXERCISE | 50,000 | — | — |
| Mar 7, 2026 | Wyrick Susan D. | See Remarks | EXERCISE | 3,250 | — | — |
| Mar 6, 2026 | Wyrick Susan D. | See Remarks | EXERCISE | 10,416 | — | — |
| Mar 6, 2026 | Harr Steve | President & CEO | EXERCISE | 41,666 | — | — |
| Mar 5, 2026 | Wyrick Susan D. | See Remarks | AWARD | 45,833 | — | — |
| Mar 5, 2026 | Wyrick Susan D. | See Remarks | AWARD | 206,250 | — | — |
| Mar 5, 2026 | Harr Steve | President & CEO | AWARD | 200,000 | — | — |
| Mar 5, 2026 | Harr Steve | President & CEO | AWARD | 900,000 | — | — |
| Mar 3, 2026 | Wyrick Susan D. | See Remarks | TAX W/H | 491 | $3.91 | $1.9K |
| Mar 2, 2026 | Wyrick Susan D. | See Remarks | EXERCISE | 1,525 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
BEARISH
PRESS-RELEASE
6/10
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21
May 11, 2026
NEUTRAL
8-K
4/10
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than t
May 11, 2026
NEUTRAL
DEFA14A
4/10
Sana Biotechnology's board is seeking shareholder approval to elect three Class II directors and rat
Apr 24, 2026
NEUTRAL
8-K
2/10
Sana Biotechnology reclassified director Steven D. Harr, M.D. from a Class I to a Class III director
Apr 24, 2026
BULLISH
8-K
6/10
Sana Biotechnology entered into a stock purchase agreement with Mayo Clinic, selling 7.5 million sha
Apr 13, 2026
BULLISH
7/10
Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the developmen
Apr 13, 2026
BULLISH
8/10
Sana Biotechnology announced 14-month data from a first-in-human study showing that its hypoimmune (
Mar 13, 2026
BULLISH
8/10
Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical a
Mar 3, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 15 analysts: 6 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.57 mean target
+219.8% upside
Strong Buy (1.44)
$7.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $2.68 |
| Target Low | $7.00 |
| Target Mean | $8.57 |
| Target Median | $7.00 |
| Target High | $12.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.44) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.13 | $-0.10 | 25.0% | +18.2% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.12 | $-0.14 | $-0.10 | 17.8% | +17.8% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.60 | $-0.68 | $-0.53 | 11.1% | -2.6% | 0↑ 2↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.54 | $-0.62 | $-0.42 | 9.5% | -1.4% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.147 | +0.027 |
| 30d ago | $-0.147 | +0.027 |
| 60d ago | $-0.157 | +0.037 |
| 90d ago | $-0.100 | -0.020 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 12, 2026
short_volume
Short Volume: SANA — 56.0% short (0.5M / 0.8M)
Short: 455,997 | Exempt: 1,067 | TRF Vol: 814,033 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: SANA — 61.3% short (0.8M / 1.3M)
Short: 773,371 | Exempt: 125 | TRF Vol: 1,262,145 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: SANA — 71.2% short (0.9M / 1.2M)
Short: 850,511 | Exempt: 1,357 | TRF Vol: 1,194,024 | Short Ratio: 71.2% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: SANA — 67.0% short (2.5M / 3.7M)
Short: 2,502,501 | Exempt: 528 | TRF Vol: 3,733,086 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: SANA — 62.2% short (1.1M / 1.8M)
Short: 1,119,295 | Exempt: 57,101 | TRF Vol: 1,798,535 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: SANA — 60.6% short (1.4M / 2.4M)
Short: 1,429,140 | Exempt: 68,575 | TRF Vol: 2,358,249 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: SANA — 67.3% short (0.8M / 1.2M)
Short: 776,813 | Exempt: 3,559 | TRF Vol: 1,154,806 | Short Ratio: 67.3% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SANA — 63.8% short (0.9M / 1.4M)
Short: 879,802 | Exempt: 985 | TRF Vol: 1,379,806 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SANA — 58.3% short (0.8M / 1.4M)
Short: 835,656 | Exempt: 14,384 | TRF Vol: 1,433,424 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 27, 2026
routine
Sana Biotechnology to Present at June 2026 Investor Conferences
<p>SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients throug
May 27, 2026
short_volume
Short Volume: SANA — 56.3% short (0.7M / 1.2M)
Short: 656,665 | Exempt: 1,237 | TRF Vol: 1,167,271 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SANA — 58.6% short (0.5M / 0.8M)
Short: 484,258 | Exempt: 1,796 | TRF Vol: 825,911 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: SANA — 70.1% short (0.7M / 0.9M)
Short: 656,084 | Exempt: 26 | TRF Vol: 935,655 | Short Ratio: 70.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SANA — 66.8% short (1.0M / 1.6M)
Short: 1,045,634 | Exempt: 100 | TRF Vol: 1,565,792 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SANA — 67.0% short (0.8M / 1.2M)
Short: 832,985 | Exempt: 10,881 | TRF Vol: 1,243,565 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)